At a glance
ClinicalIndex Comparison Record- ✓Clinically suspected or biopsy-confirmed pancreatic adenocarcinoma
- ✓Planned standard of care surgery with curative intent
- ✓Life expectancy greater than 12 weeks
- ✓Karnofsky performance status at least 70% or ECOG/Zubrod ≤1
- ✕Received investigational drug within 30 days prior to first dose
- ✕Myocardial infarction, cerebrovascular accident, uncontrolled CHF, or unstable angina within 6 months
- ✕History of infusion reactions to panitumumab or monoclonal antibodies
- ✕Pregnant or breastfeeding
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Pancreas Cancer During Surgical Procedures
In Brief
A Phase 2 clinical trial evaluating Fluorescence Imaging, Panitumumab, and 1 other intervention for Pancreatic Adenocarcinoma. Currently recruiting, targeting 27 participants across 1 site.
Detailed Summary
This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with pancreatic cancer.
Study Details
Timeline
Interventions
Undergo fluorescence imaging
Given IV
Given IV